7RA Stock Chart & Stats
€25.20
€0.00(0.00%)
At close: 4:00 PM EDT
€25.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€9.65 - €30.80
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€2.30B
Enterprise Value€5.30K
Total Cash (Recent Filing)€171.29M
Total Debt (Recent Filing)€2.56B
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Nov 04, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.45
Shares Outstanding93,100,270
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.39
P/FCF Ratio-2.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€31.13Price Target Upside23.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)1.32
Revenue Forecast (FY)€2.97B
Bulls Say, Bears Say
Bulls Say
Behavioral Health ContinuumAcadia serves multiple behavioral-health needs and acuity levels through inpatient, residential and outpatient settings. This integrated continuum can support referrals, step-down care and patient retention across programs, creating a durable platform for growth as demand for mental-health and substance-use treatment remains broad.
Facility Expansion ExecutionThe company is expanding capacity through new acute facilities and joint ventures, while recent cohorts are ahead of start-up targets. Successful licensing, openings and occupancy ramps can add durable revenue and EBITDA as new beds mature and fixed assets are utilized more fully.
Cash Flow And Debt ReductionStrong quarterly cash generation and debt repayment demonstrate improving financial execution despite recent earnings pressure. If sustained, better free-cash-flow conversion can reduce leverage, strengthen liquidity and provide greater flexibility to fund capacity additions without relying as heavily on financing.
Bears Say
Earnings DeteriorationThe sharp shift from 2024 profitability to substantial TTM losses indicates that earnings power remains weak and volatile. A revenue contraction further limits operating leverage, making it harder for the company to absorb cost increases, support expansion and generate dependable shareholder returns.
Leverage And Free Cash FlowHigher leverage reduces financial flexibility at a time when profitability is unstable, while negative TTM free cash flow shows that operating cash has not consistently covered investment needs. Together, these conditions can constrain capital allocation and increase dependence on future cash-flow improvement.
Professional Liability CostsRising professional-liability costs can create a persistent margin headwind and make earnings less predictable. Management's inability to determine whether additional actuarial adjustments will occur adds uncertainty to future profitability, cash generation and the reliability of current operating forecasts.
7RA FAQ
What was Acadia Healthcare’s price range in the past 12 months?
Acadia Healthcare lowest stock price was €9.65 and its highest was €30.80 in the past 12 months.
What is Acadia Healthcare’s market cap?
Acadia Healthcare’s market cap is €2.30B.
When is Acadia Healthcare’s upcoming earnings report date?
Acadia Healthcare’s upcoming earnings report date is Nov 04, 2026 which is in 35 days.
How were Acadia Healthcare’s earnings last quarter?
Acadia Healthcare released its earnings results on Jul 28, 2026. The company reported €0.334 earnings per share for the quarter, beating the consensus estimate of €0.304 by €0.03.
Is Acadia Healthcare overvalued?
According to Wall Street analysts Acadia Healthcare’s price is currently Undervalued.
Does Acadia Healthcare pay dividends?
Acadia Healthcare does not currently pay dividends.
What is Acadia Healthcare’s EPS estimate?
Acadia Healthcare’s EPS estimate is 0.41.
How many shares outstanding does Acadia Healthcare have?
Acadia Healthcare has 93,100,270 shares outstanding.
What happened to Acadia Healthcare’s price movement after its last earnings report?
Acadia Healthcare reported an EPS of €0.334 in its last earnings report, beating expectations of €0.304. Following the earnings report the stock price went down -10.87%.
Which hedge fund is a major shareholder of Acadia Healthcare?
Currently, no hedge funds are holding shares in DE:7RA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acadia Healthcare Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€31.13 (23.52% Upside)
€31.13 (23.52% Upside)
Blogger Sentiment
Bullish
DE:7RA Sentiment 71%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acadia Healthcare
Acadia Healthcare Company, Inc. specializes in delivering a comprehensive range of behavioral health services, with its operations spanning the United States and Puerto Rico. Patients receive care in diverse environments, including acute inpatient psychiatric hospitals, specialized treatment facilities, long-term residential centers, and outpatient clinics. As of March 31, 2022, the company managed an extensive network consisting of 238 behavioral healthcare facilities, collectively providing approximately 10,600 beds. Established in 2005, Acadia Healthcare is headquartered in Franklin, Tennessee.
7RA Company Deck
7RA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: management reported results at or above guidance, strong free cash flow, substantial debt reduction, improving performance from new facilities, operational gains, and confidence in the full-year outlook. Offsetting issues included flat reported revenue, the impact of New York Medicaid changes, a significant professional liability reserve adjustment, CTC performance below expectations, start-up losses, and uncertainty around government investigation costs. The highlights significantly outweighed the lowlights.View all DE:7RA earnings summaries7RA Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€31.13
▲(23.52% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Community Health
―
HCA Healthcare
―
Healthcare Services
―
Universal Health
―
Lifestance Health Group
―











